(2S,4R)-BOC-4-苯甲酰氧基脯氨酸甲酯 | 121147-94-2

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 脯氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (2S,4R)-BOC-4-苯甲酰氧基脯氨酸甲酯
• 英文名称: 1-tert-butyl 2-methyl (2S,4S)-4-((benzoyl)oxy)-1,2-pyrrolidinedicarboxylate
• 英文别名: (2S,4S)-2-methyl N-Boc-4-(benzoyloxy)pyrrolidine-2-carboxylate；(2S,4S)-1-tert-Butyl 2-methyl 4-(benzoyloxy)pyrrolidine-1,2-dicarboxylate；1-O-tert-butyl 2-O-methyl (2S,4S)-4-benzoyloxypyrrolidine-1,2-dicarboxylate
• CAS: 121147-94-2
• 化学式: C₁₈H₂₃NO₆
• 分子量: 349.384
• InChiKey: HCMBKFLKTBCNNU-KBPBESRZSA-N

物化性质

• 沸点：
  438.6±45.0 °C(Predicted)
• 密度：
  1.22±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  82.1
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2S,4R)-BOC-4-苯甲酰氧基脯氨酸甲酯 在 potassium carbonate 作用下， 以 甲醇 为溶剂， 反应 1.0h， 以98.4%的产率得到N-Boc-顺式-4-羟基-L-脯氨酸甲酯
  参考文献：
  名称：

  6（R）-和6（S）-氟代对苯二甲胺的合成及抗菌活性As：氟作为测试手性记忆（MOC）记忆力的探针

  摘要：

  利用Kim和他的同事们开发的优美策略，已经完成了6（R）-和6（S）-氟代苯丙胺的合成。通过关键的分子内醛醇缩合反应形成单个非对映异构体，并且通过X射线衍射晶体学明确地证实了两种产物。该反应表明氟酰胺效应不能与手性（MOC）效应的记忆竞争，从而进一步证明了MOC效应在不对称合成中的强大作用。在这项工作中进行的生物学测试表明，天然提取物的抗菌活性的原理可能不是penibruguieramineA。

  DOI：

  10.1016/j.jfluchem.2018.01.002
• 作为产物：
  描述：

  N-Boc-反式-4-羟基-L-脯氨酸甲酯 在 三乙胺 作用下， 以 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 3.0h， 生成 (2S,4R)-BOC-4-苯甲酰氧基脯氨酸甲酯
  参考文献：
  名称：

  Synthesis and Biological Activity of 1-Phenylsulfonyl-4-Phenylsulfonylaminopyrrolidine Derivatives as Thromboxane A 2 Receptor Antagonists

  摘要：

  The synthesis and biological activity of novel 1-phenylsulfonyl-4- phenylsulfonylaminopyrrolidine analogues are described. All compounds were produced through modification of the substituent formally corresponding to the 1,3-dioxane ring system and the omega-octenol side chain of thromboxane A(2) (TXA(2)), in reference to the structure of Daltroban. Several compounds were found to be potent TXA(2) receptor antagonists. Compound 51a was the most effective inhibitor of 9.11-epoxymethano PGH(2) (U-46619)-induced rat aortic strip contraction (IC50 = 0.48 nM). (C) 2002 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0968-0896(01)00397-2

文献信息

• NOVEL AMINO PYRIMIDINE DERIVATIVES
  申请人：ANGST Daniela

  公开号：US20150152068A1

  公开（公告）日：2015-06-04

  The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

  本发明描述了新的氨基嘧啶衍生物及其药用盐，这些衍生物似乎与布鲁顿酪氨酸激酶（Btk）相互作用。因此，这些新型氨基嘧啶可能在治疗自身免疫性疾病、炎症性疾病、过敏性疾病、气道疾病（如哮喘和慢性阻塞性肺病（COPD））、移植排斥、血液起源或实体肿瘤等癌症方面具有有效性。
• [EN] NOVEL AMINO PYRIMIDINE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS D'AMINOPYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2015079417A1

  公开（公告）日：2015-06-04

  The present invention describes new amino pyrimidine derivatives of formula (I) and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

  本发明描述了新的氨基嘧啶衍生物的化学式(I)及其药用盐，这些衍生物似乎与布鲁顿酪氨酸激酶（Btk）相互作用。因此，这些新型氨基嘧啶可能在治疗自身免疫性疾病、炎症性疾病、过敏性疾病、气道疾病（如哮喘和慢性阻塞性肺病（COPD））、移植排斥、血液起源或实体肿瘤等癌症方面具有有效性。
• Pyrrolidine derivatives as antiasthmatics
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US04916152A1

  公开（公告）日：1990-04-10

  The invention relates to novel compounds of the formula: ##STR1## wherein R.sup.1 is hydrogen, lower alkoxycarbonyl, phenylsulfonyl, phenylsulfonyl substituted with 1 to 3 substituent(s) selected from the group consisting of halogen, nitro, lower alkoxy, mono (or di or tri)halo(lower)alkyl and lower alkyl, phenylcarbamoyl, lower alkylsulfonyl, benzoyl or thienylsulfonyl; R.sup.2 is phenylsulfonyl or phenylsulfonyl substituted with 1 to 3 substituent(s) selected from the group consisting of halogen, lower alkyl, lower alkoxy and mono(or di or tri)halo(lower)alkyl, R.sup.3 is carboxy(lower)alkyl, lower alkyl substituted with carboxy and 1 to 3 halogen atom(s), esterified carboxy(lower)alkyl, carbamoyl(lower)alkyl, lower alkylsulfonylcarbamoyl(lower)alkyl, phenylsulfonylcarbamoyl(lower)alkyl, carboxyphenyl, esterified carboxyphenyl, carboxy, esterified carboxy, hydroxy(lower)alkyl, sulfino(lower)alkyl, phosphono(lower)alkyl, di(lower)alkoxyphosphoryl(lower)alkyl or halo(lower)alkyl, R.sup.7 is hydrogen or lower alkyl, and A is ##STR2## in which R.sup.8 is hydrogen or lower alkyl, or a pharmaceutically acceptable salt thereof, useful as therapeutic agents for thrombosis, asthma and nephritis.

  本发明涉及新型化合物的公式：##STR1##其中R.sup.1是氢，低碳酰氧基，苯基磺酰基，苯基磺酰基，其上被1至3个取代基取代，所述取代基选自卤素，硝基，低烷氧基，单（或双或三）卤（低）烷基和低烷基，苯基氨基甲酰基，低烷基磺酰基，苯甲酰基或噻吩基磺酰基; R.sup.2是苯基磺酰基或苯基磺酰基，其上被1至3个取代基取代，所述取代基选自卤素，低烷基，低烷氧基和单（或双或三）卤（低）烷基，R.sup.3是羧基（低）烷基，低烷基，其上被羧基和1至3个卤素原子取代，酯化的羧基（低）烷基，氨基甲酰（低）烷基，低烷基磺酰氨基甲酰（低）烷基，苯基磺酰氨基甲酰（低）烷基，羧基苯基，酯化的羧基苯基，羧基，酯化的羧基，羟基（低）烷基，磺酰基（低）烷基，膦酸（低）烷基，二（低）烷氧基磷酰基（低）烷基或卤（低）烷基，R.sup.7是氢或低烷基，A是##STR2##其中R.sup.8是氢或低烷基，或其药学上可接受的盐，用作治疗血栓，哮喘和肾炎的治疗剂。
• Pyrrolidine derivatives
  申请人：Fujisawa Pharmaceutical Co., Ltd.

  公开号：US05264453A1

  公开（公告）日：1993-11-23

  This invention relates to pyrrolidine derivatives and pharmaceutically acceptable salts thereof of the structure ##STR1## where R.sup.1, R.sup.2, and R.sup.3 are as defined herein. These compounds are for pharmaceutical use in treating thrombotic diseases, asthma or nephritis.

  本发明涉及一种吡咯烷衍生物及其药学上可接受的盐，其结构为## STR1 ##其中R.sup.1，R.sup.2和R.sup.3如本文所定义。这些化合物用于药物治疗血栓性疾病，哮喘或肾炎。
• Novel Amino Pyrimidine Derivatives
  申请人：Angst Daniela

  公开号：US20160235746A1

  公开（公告）日：2016-08-18

  The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.

  本发明描述了新的氨基嘧啶衍生物及其药学上可接受的盐，它们似乎与布鲁顿酪氨酸激酶（Btk）相互作用。因此，这种新型氨基嘧啶可能在治疗自身免疫性疾病、炎症性疾病、过敏性疾病、气道疾病（如哮喘和慢性阻塞性肺疾病（COPD））、移植排斥和血液系统肿瘤或实体瘤等癌症方面具有疗效。